Three-arm NI Trial as a gold standard design 4 Three-arm NI
Test Active Control Placebo Control
Provide the opportunity of establishing the validity of the assay sensitivity via a comparison of the placebo with the active control intervention within the trial.
Provide challenges:
Ethical issue there may be ethical constraints to using a placebo Difficulty there is the added difficulty of evaluating two distinct co-objectives: evaluation of (i) the superiority of the active control intervention to placebo (AS) and (ii) the NI of the test intervention to the active control intervention.
Feasibility it may result in a trial with too large and impractical of a sample size to conduct due to the two co-objectives
Objectives
To discuss group-sequential designs (GSDs) for three-arm NI clinical trials GSDs offer the possibility to stop a trial early when evidence is overwhelming and thus offers efficiency-potentially fewer trial participants and minimizing the amount of time that participants receive a placebo, compared to fixed-sample designs.
To extend two existing approaches for evaluating AS and NI into a GS setting
Fixed margin approach (Koch and Röhmel, 2004; Hida and Tango, 2011, 2013) Fraction approach (Pigeot et al, 2003 ) To discuss a three-arm NI trial that has two co-primary objectives: AS and NI If the AS assumption does not hold, then there will be uncertainty regarding whether a NI result means that they are similarly effective or similarly ineffective. When there is a concern about the AS, to make the evaluation of objective (ii) more interpretable, evaluate a direct comparison of the control intervention (C) with the placebo (P) Three-arm NI
( 1, … , ) Objective To evaluate the superiority of transdermal rotigotine to placebo, and to evaluate NI to ropinirole, in Japanese Parkinson's disease patients on concomitant levodopa therapy. Primary endpoints The change in the unified Parkinson's disease rating scale (UPDRS) Part III (ON state) sum score from baseline to week 16 of the treatment period
Illustration Calculate the maximum sample size (MSS) and average sample number (ASN) under th alternative hypothesis for evaluating AS and NI  80 % power at the 2.5 % significance level for a one-sided test  # of planned analyses: 1 and 2.  Critical boundaries determined using Lan-DeMets error spending method (Lan and DeMets, 1983 ) with equally-spaced increment of information. 1 DF-A and DF-B for the fixed margin and the fraction approaches provide the possibility of stopping a trial early when evidence is overwhelming, thus offering efficiency (e.g., an ASN potentially 4-15 % fewer than the fixed-sample designs with equally sized groups and four analyses).
2 There are no major differences in both MSS and ASN between DF-A and DF-B for the fixed margin and the fraction approaches, although DF-A is slightly more powerful than DF-B. By using the DF-A for the fixed margin approach, the time that participants are exposed to placebo can be minimized as the DF-A allows dropping of the placebo group if AS has been demonstrated at an interim analysis 
